Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin DPPIV Inhibitor add-on Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes~* Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these~* Patients will be screened by a blood test and only those who need additional therapy can be enrolled~Exclusion Criteria:~* Patients with type 1 diabetes~* Patients with very poorly controlled diabetes~* Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Dapagliflozin 10 mg tablet
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).